ElectroCore

electroCore, Inc.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

electroCore, Inc. (Nasdaq: ECOR) is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD.[1] The current chief executive officer is Daniel S. Goldberger.[2] electroCore[3] has one product called gammaCore,[4][5] a non-invasive, commercially available product that uses vagus nerve stimulation.[6]

History

edit edit source

The company was co-founded by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD, in 2005.[1]

In 2018, electroCore, Inc. went public with a $78 million IPO.[7]

On March 27, 2020, electroCore announced a common stock purchase agreement of up to $25 million with Chicago-based institutional investor Lincoln Park Capital Fund, LLC.[8]

In 2025, the company acquired NeuroMetrix, adding the Quell electrical nerve stimulation platform to its product portfolio.[9]

Products

edit edit source

gammaCore Sapphire CV

edit edit source

In July 2020, the FDA gave an emergency COVID-19 authorization for gammaCore Sapphire CV, a vagus nerve stimulation device, aimed at reducing exacerbations in people potentially affected by the novel coronavirus and have difficulty breathing due to asthma.[10]

Truvaga

edit edit source

A VNS product owned by Electrocore.[11]

References

edit edit source
  1. ^ a b "electroCore Inc. Company & People | ECOR". Barron's. Retrieved 2024-12-12. Wikipedia revision 1365436764, retrieved 2026-11-19
  2. ^ "Nerve stimulation device maker electroCore goes public with $78M IPO | FierceBiotech". www.fiercebiotech.com. Retrieved 2019-03-06. Wikipedia revision 1365436764, retrieved 2026-11-19
  3. ^ "This hand-held device is approved to treat cluster headaches". NBC News. Retrieved 2019-03-06. Wikipedia revision 1365436764, retrieved 2026-11-19
  4. ^ "ElectroCore wins cluster headache FDA 510(k) indication for GammaCore". MassDevice. 2018-11-28. Retrieved 2019-03-06. Wikipedia revision 1365436764, retrieved 2026-11-19
  5. ^ "Nerve Stimulator Approved for Cluster Headache". Pain News Network. Retrieved 2019-03-06. Wikipedia revision 1365436764, retrieved 2026-11-19
  6. ^ "Term Sheet -- Friday, June 22". Fortune. Retrieved 2019-03-06. Wikipedia revision 1365436764, retrieved 2026-11-19
  7. ^ Hale, Conor (2018-06-22). "Nerve stimulation device maker electroCore goes public with $78M IPO | Fierce Biotech". www.fiercebiotech.com. Retrieved 2024-12-16. Wikipedia revision 1365436764, retrieved 2026-11-19
  8. ^ "BRIEF-electroCore Announces Common Stock Purchase Agreement For Up To $25 Mln With Lincoln Park Capital". Reuters. 2020-03-27. Retrieved 2020-03-31. Wikipedia revision 1365436764, retrieved 2026-11-19
  9. ^ Hale, Conor (2024-12-20). "ElectroCore buys NeuroMetrix and its Quell fibromyalgia wearable". www.fiercebiotech.com. Retrieved 2026-07-22. Wikipedia revision 1365436764, retrieved 2026-11-19
  10. ^ electroCore (2020-07-13). "electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients". GlobeNewswire News Room. Retrieved 2020-07-15. Wikipedia revision 1365436764, retrieved 2026-11-19
  11. ^ https://www.truvaga.com/vagus-nerve-science/ truvaga.com/vagus-nerve-science/ · bare citation; no publisher or title recorded · Wikipedia revision 1365436764, retrieved 2026-11-19

Text derived from https://en.wikipedia.org/w/index.php?oldid=1365436764 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “ElectroCore” revision 1365436764 · retrieved 2026-10-20 date of foundation (×1) · confidence 0.95 revision URL